CDK inhibitors in hormone receptor positive advanced breast cancer

Bilge AKTAS

doi:https://doi.org/10.5472/mmj.77406

Makale detayları

CDK inhibitors in hormone receptor positive advanced breast cancer

Yazarlar:

Bilge AKTAS

Yayıncı:

Marmara University

Dergi:

Marmara Medical Journal 2015 Vol.28 Issue 1, pp.35-39

Belge Tipi:

Makale

Yayın Tarihi:

9/2015

Belge Dili:

İngilizce

Document ID (Org No.):

2000544882

Sıklık:

Aylık

eISSN:

1309-9469

pISSN:

1019-1941

DOI:

https://doi.org/10.5472/mmj.77406

Özet:

 


Endocrine treatment is the current first line treatment in ER+advanced breast cancer with a requirement of predictivebiomarkers to the treatment and different approaches forendocrine resistance risk. Cyclin dependent kinases (CDKs)are regulating each step of cellular division in mammaliancell cycle and are hyperactivated in cancer cells causingcancer progression. Next generation pan-CDK inhibitors arein clinical development, while clinical trials in breast cancer,particularly in ER+ subtype where the greatest growthinhibition has been observed. Here I will review the datafrom this new class of drugs.Keywords: CDK inhibitors, Hormone positive advancedbreast cancer, Targeted therapies, Palbociclib, Endocrinetherapy resistance

.

Makale detayları

CDK inhibitors in hormone receptor positive advanced breast cancer

Yazarlar: Bilge AKTAS

Yayıncı: Marmara University

Dergi: Marmara Medical Journal 2015 Vol.28 Issue 1, pp.35-39

Belge Tipi: Makale

Yayın Tarihi: 9/2015

Belge Dili: İngilizce

Document ID (Org No.): 2000544882

Sıklık: Aylık

eISSN: 1309-9469

pISSN: 1019-1941

DOI: https://doi.org/10.5472/mmj.77406

Sayı

Yazarlar:

Bilge AKTAS

Yayıncı:

Marmara University

Dergi:

Marmara Medical Journal 2015 Vol.28 Issue 1, pp.35-39

Belge Tipi:

Makale

Yayın Tarihi:

9/2015

Belge Dili:

İngilizce

Document ID (Org No.):

2000544882

Sıklık:

Aylık

eISSN:

1309-9469

pISSN:

1019-1941

DOI:

https://doi.org/10.5472/mmj.77406